Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction
- 21 November 2008
- journal article
- Published by Wiley in BJU International
- Vol. 102 (11) , 1651-1657
Abstract
OBJECTIVE: To determine how partial bladder outlet obstruction (PBOO) in a rat model affects erectile function, and whether an uroselective α1‐adrenoceptor antagonist, alfuzosin (Sanofi‐Aventis, Paris, France) attenuates any erectile dysfunction (ED). MATERIALS AND METHODS: Adult male Sprague‐Dawley rats (120) were randomized into four groups: 1, sham‐operated; 2, alfuzosin‐treated; 3, PBOO; and 4, alfuzosin‐treated with PBOO. Groups 3 and 4 were subjected to PBOO for 6 weeks by ligation of the urethra, while groups 2 and 4 rats received daily oral alfuzosin (10 mg/day) for 6 weeks. In vivo erectile responses were monitored by evaluating ratios of intracavernosal pressure (ICP)/mean arterial pressure, and total ICP (area under the curve). Organ‐bath studies were performed on corpus cavernosum smooth muscle (CCSM) strips. Nitric oxide synthase (NOS) expression was determined immunohistochemically (IHC) for neuronal (n)NOS and by Western blot analysis for endothelial (e) and inducible (i) NOS protein. RESULTS: Rats with PBOO showed lower erectile responses than controls. Maximum electrical field stimulation‐mediated and endothelium‐dependent acetylcholine‐induced relaxations and contractile responses to phenylephrine were significantly reduced in CCSM strips from the PBOO group. The NO donor sodium nitroprusside completely relaxed CCSM from rats in all groups. IHC analyses showed decreased expression of nNOS in PBOO groups compared with controls; by contrast, protein expression of eNOS and iNOS was increased. Alfuzosin‐treatment partially attenuated functional and molecular changes in penises of PBOO rats. CONCLUSION: Rats with PBOO show ED, most likely due to altered NOS expression and NO bioavailability. The α‐adrenoreceptor antagonist alfuzosin reversed this ED by altering sympathetic tone, increasing NO‐induced relaxation and augmenting blood flow in the penis. This study suggests a rationale for further clinical trials using combinations of α‐adrenoceptor antagonists and phosphodiesterase‐5 inhibitors in patients with ED and lower urinary tract symptoms.Keywords
This publication has 38 references indexed in Scilit:
- A review of combination therapy in patients with benign prostatic hyperplasiaClinical Therapeutics, 2007
- Lower urinary tract symptoms and erectile dysfunction are highly prevalent in ageing menBJU International, 2005
- Increased corpus cavernosum smooth muscle tone associated with partial bladder outlet obstruction is mediated via Rho-kinaseAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2005
- Erectile Dysfunction and Lower Urinary Tract Symptoms Secondary to BPHEuropean Urology, 2005
- Alfuzosin Improves Penile Erection Triggered by Apomorphine in Spontaneous Hypertensive RatsEuropean Urology, 2004
- Lower Urinary Tract Symptoms and Male Sexual Dysfunction: The Multinational Survey of the Aging Male (MSAM-7)European Urology, 2003
- Alteration in expression of myosin isoforms in detrusor smooth muscle following bladder outlet obstructionAmerican Journal of Physiology-Cell Physiology, 2003
- Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosumBJU International, 2003
- Effect of Doxazosin on rat urinary bladder function after partial outlet obstructionNeurourology and Urodynamics, 2002
- Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective α-blockerUrology, 2001